VEMURAFENIB

BRAF V600 Mutation

Technische Universität DresdenSmall moleculePhase 2Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 89/ 100

Competitive context

20 Active assets in the BRAF V600 Mutation cohort.

Asset / Sponsor	Phase	Rating
Binimetinib UNICANCER	Phase 2	BB
Encorafenib UNICANCER	Phase 2	B
Nivolumab H. Lee Moffitt Cancer Center and Research Institute	Phase 2	B
Cobimetinib ABM Therapeutics Corporation	Phase 2	B
gsk1120212 Xynomic Pharmaceuticals, Inc.	Phase 2	B

View all 21 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant

BB

Indicative ·

66 / 100

metastatic melanomaDormant

B

Indicative ·

63 / 100

hematopoietic and lymphoid system neoplasmDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.